Table 1.

Dosing regimen of chloroquine, hydroxychloroquine and tocilizumab for treatment of COVID-19.

Drug	Dosage		Duration
Chloroquine phosphatea	Only for adults aged 18–65 years		7 days
	Body weight >50 kg: 500 mg, twice per day
	Body weight ≤50 kg: 500 mg, twice per day, for Days 1–2 followed by 500 mg once per day for Days 3–7
	Contraindications	Cardiac diseases or conditions
	Precautions	Pay close attention to drug–drug interactions and adverse reactions during the use of chloroquine
Hydroxychloroquine sulphateb	200 mg, three times per day		10 days
	Contraindications	Retinopathy, G6PD deficiency, QT prolongation
Tocilizumab	First dose: 4–8 mg/kg (400 mg recommended) diluted with 0.9% sodium chloride injection into 100 mL
	Intravenous infusion time: ≥1 h
	Second dose: if the first dose is not effective, a second dose can be given after 12 h (same dose as before)
	Total number of administrations: ≤2
	Maximum single dose: ≤800 mg
	Precautions	Pay attention to anaphylaxis
	Contraindications	Active infections such as tuberculosis

G6PD, glucose-6-phosphate dehydrogenase.

^aThis dosing regimen of chloroquine is provided in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) issued by the National Health Commission of China.

^bThis dosing regimen of hydroxychloroquine was used in an open-label non-randomized clinical trial conducted in France to investigate the efficacy of hydroxychloroquine and azithromycin therapy in the treatment of COVID-19. Breastfeeding and pregnant patients and children were excluded from this clinical trial.